Earlier this month, the FDA approved Bildyos and Bilprevda (denosumab-nxxp), 2 additional denosumab biosimilars for Prolia ...

The FDA has granted fast track designation to the antibody-drug conjugate (ADC) CRB-701 for the treatment of recurrent or ...

Cabozantinib, a tyrosine kinase inhibitor (TKI), was recently approved for patients with previously treated pancreatic NETs.

Pierre Gholam, MD, observes the improvements in outcomes with lenvatinib seen in recent trials of unresectable hepatocellular carcinoma compared with the original phase 3 REFLECT trial.

The US FDA has granted breakthrough therapy designation to the novel antibody-drug conjugate (ADC) raludotatug deruxtecan ...

Researchers explore innovative macrocyclic peptides to target small cell lung cancer, revealing promising therapeutic ...

Ligufalimab receives FDA orphan drug designation for AML, showcasing promising efficacy and safety in treating hematologic ...

During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the ...

During a live event, Raajit K. Rampal, MD, PhD, discussed ropeginterferon's potential to reduce JAK2 allele burden in ...

Kidney injury molecule–1 (KIM-1) has emerged as a potential prognostic biomarker for response to therapy and could be used to ...

During a live event, Shirish M. Gadgeel, MD, discussed different management approaches to the improve tolerability of ...

The COCOON study was conducted to determine if an enhanced dermatology management strategy, known as COCOON DM, could reduce ...